Novo Nordisk Pharmatech closes distribution agreement for Russia and CIS countries
Novo Nordisk Pharmatech has entered an extensive partnership agreement for Russia and CIS countries with Czech company IMCoPharma.
BY ANDREAS LØNSTRUP, TRANSLATED BY NIELSINE NIELSEN
The ingredient-producing subsidiary of Novo Nordisk, Novo Nordisk Pharmatech, has entered an agreement with IMCoPharma for the distribution of the company's Quats (synthetic molecules) to the healthcare industry in Russia and countries in the Commonwealth of Independent States (CIS), according to Pharmaceutical Business review.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
-go.jpg)
